In 2002, Kauff et al
1 and Rebbeck et al
2 published the first 2 studies demonstrating that risk-reducing salpingo-oophorectomy (RRSO) decreased the risk for breast and ovarian or fallopian tube cancer in women with mutations in the
BRCA1 (OMIM 113705) (
BRCA1+ women) or
BRCA2 (OMIM 600185) (
BRCA2+ women) gene. Subsequent studies have confirmed that RRSO not only reduces the risk for ovarian or fallopian tube cancer by 80% to 90% and the risk for breast cancer by 40% to 70%
3-5 but also reduces disease-specific and overall mortality.
4,5